Seqirus, part of the CSL Limited Group, has already begun the distribution of the doses of the flu vaccine that will be administered by the Italian regions to citizens starting in the next few weeks. The company announces it in a note, recalling that “the start of the flu vaccination campaign for the 2021-2022 season is just around the corner. Aifa gives the timing and authorizes the updating of the composition of flu vaccines. And it will be essential that, at the start of immunization, the doses of vaccine necessary to take off the important prevention initiative, offering targeted responses based on the characteristics of the subjects “. “Seqirus has always been at the forefront in the fight against influenza and makes all its skills available to continue to be an excellent partner of Italian public health – declares Maura Cambiaggi, General Manager Seqirus Italy – We are proud to have contributed to significantly last year to the achievement of high coverage rates and we are confident that equally positive results can be achieved this season as well. For us it is a priority to protect citizens from flu viruses and the vaccines required by the Regions are already being delivered, in full compliance of the times recommended by the circular of the Ministry of Health – he underlines – in order to protect the most fragile categories as soon as possible, such as the elderly in a difficult epidemiological situation. also of the persistence of the Sars-Cov-2 pandemic, and will allow to alleviate the pressure on the national health system already strongly tried by the Covid-19 pandemic, as well as favoring the differential diagnosis especially in the most vulnerable subjects. Furthermore, multiple recently published studies suggest that influenza vaccination can help mitigate the serious complications caused by Covid-19, facilitating a more favorable course of the disease “. For Seqirus” the important thing is to offer a ‘tailor-made’ response for everyone. . This is why it must be remembered that not all vaccines are the same “, the company specifies.” The functioning of our immune system – he explains – is in fact based on a complex mechanism of interaction between a multiplicity of different cells involved in creating an efficient system of defense of the organism against foreign agents. The cells of the immune system, as we age, undergo a progressive biological aging process, known as immunosenescence. Among other things, there is a decrease in the functioning of T and B lymphocytes: the changes that occur at the cellular level affect the reduction of the ability to produce an adequate immune response in the elderly. This is why it is essential to offer each person the most suitable vaccine for its characteristics, based on age and the presence of any concomitant pathologies “.” Scientific research is moving increasingly towards precision medicine also applied to vaccines and Seqirus , thanks to its cutting-edge research and development capacity and its portfolio of differentiated products – concludes the company – will make available for the 2021-2022 flu campaign both the new adjuvanted quadrivalent vaccine, specifically indicated for the active prophylaxis of influence in subjects over 65 years of age, than the quadrivalent one produced on cell cultures and indicated from 2 years of age “.